I n 2016, dual antiplatelet therapy (DAPT) assumes its 20th anniversary since the publication of the first randomized clinical trial establishing the superiority of DAPT over anticoagulant therapy among patients undergoing percutaneous coronary intervention (PCI) (Figure) . 1 Because then, both antiplatelet therapy and PCI have undergone continued refinement. Clopidogrel substituted ticlopidine, and subsequently, more potent oral and intravenous P2Y 12 receptor inhibitors (prasugrel, ticagrelor, and cangrelor) entered the field of DAPT, whereas the advent of metallic drug-eluting stents (DES) and, more recently, completely bioresorbable scaffolds marked important milestones in the field of PCI. For several years, the duration of DAPT did not play a critical role in the pharmacological therapy after PCI. Indeed, DAPT was prescribed for 2 to 6 months after PCI in pivotal trials leading to the approval of the early-generation DES by the US Food and Drug Administration. [2] [3] [4] It was only in the aftermath of increasing safety concerns related to the phenomenon of very late stent thrombosis after implantation of early-generation DES that prolongation of DAPT to 12 months was recommended by the American College of Cardiology Foundation/ American Heart Association/Society for Cardiac Angiography and Interventions guidelines. 5 In the meantime, coronary stent technology rapidly evolved with the transition from early-to newer generation DES, featuring lower drug loads, thinner stent struts, more biocompatible or biodegradable polymers, and eventually improved patient outcomes. 6 Although newgeneration DES are currently recognized as default therapy in almost all lesion and patient subsets, the optimal duration of DAPT still remains the subject of debate. 6,7
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Available evidence suggests that prolonging DAPT in patients undergoing PCI is associated with a lower risk of long-term atherothrombotic events, including stent thrombosis and myocardial infarction, benefits that are partially offset by an increased risk of clinically relevant bleeding. 6, 8 Although these data are derived from >10 randomized trials involving >30 000 patients, they are driven to a large extent by the DAPT study that included 9961 patients randomly assigned to 12-month versus 30-month DAPT after DES implantation. 9 Several converging lines of evidence, however, indicate that the effects of prolonged DAPT on stent-related outcomes may be attenuated by new-generation DES and that previous concerns of DES safety are replaced by focus on long-term patient-related outcomes. 6, 9 In this issue of Circulation: Cardiovascular Interventions, Han et al 10 report the results of a randomized trial comparing 6-month versus 12-month DAPT among 1829 patients who received a thin-strut, cobalt-chromium, polylactide-co-glycolide, biodegradable polymer-based, sirolimus-eluting stent (Tivoli; Essen Tech, Beijing, China). The study population represents the experimental arm of the Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for the Treatment of Coronary Revascularization (I-LOVE-IT 2) trial that compared the biodegradable polymer sirolimus-eluting stents against durable polymer sirolimus-eluting stents among 2737 patients. 11 At 1-year, 6-month DAPT was found noninferior to the 12-month DAPT regimen for the primary end point target-lesion failure, a composite of cardiac death, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization (6.8% versus 5.9%; P for noninferiority=0.0065). The rate of target-lesion failure (7.5% versus 6.3%; P=0.32) and net adverse clinical events, a composite of all-cause mortality, myocardial infarction, stroke, or major bleeding (7.8% versus 7.3%; P=0.60), was similar at 18 months of follow-up. Of note, there were no differences in rates of the individual components of the primary end point, as well as definite or probable stent thrombosis (0.6% versus 0.2%; P=0.25). Consistent findings were observed in the subgroup of patients presenting with ST-segment-elevation myocardial infarction (n=248) and non-ST-segment-elevation acute coronary syndrome (n=1248). Bleeding events (type ≥3 according to Bleeding Academic Research Consortium Criteria) occurred at comparable rates (5.5% versus 5.7%; P=0.90) although rates of bleeding were somewhat higher than in previously reported trials despite the prevalent use (>90%) of radial access with the corollary effect to reduce access-site related bleeding.
What are the clinical implications of the study? First, the study provides the largest source of data comparing different durations of DAPT among patients treated with metallic, DAPT With New-Generation DES biodegradable polymer-based DES. Before the I-LOVE-2 trial, only 763 (54%) and 336 (8%) patients enrolled in the Second Generation Drug-Eluting Stent Implantation Followed by Six-Versus Twelve-Month Dual Antiplatelet Therapy (SECURITY) and Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) trials, respectively, had been treated with biodegradable polymer-based DES. 12, 13 However, there was no randomization according to stent type in SECURITY and ISAR-SAFE, and no data were specifically provided for patients who had been implanted solely with biodegradable polymer-based DES. 12, 13 Second, the findings are in line with 6 other randomized trials comparing ≤6-month DAPT versus 12-month DAPT. In a network meta-analysis, Palmerini et al 8 found that ≤6-month versus 12-month DAPT was associated with a similar risk of all-cause mortality (hazard ratio, 0.95; 95% credible intervals, 0.76-1.20), myocardial infarction (hazard ratio, 1.00; 95% credible interval, 0.75-1.30), and definite or probable stent thrombosis (hazard ratio, 1.10; 95% credible interval, 0.66-1.70) but a lower risk of major bleeding (hazard ratio, 0.59; 95% credible interval, 0.36-0.95). Individually, none of these studies reported a significant difference in the risk of major bleeding. Although these data indicate that previous concerns of stent-related outcomes are less dependent on DAPT duration, they do not resolve the competing risks of long-term atherothrombotic versus bleeding adverse events associated with prolonged DAPT.
Third, ≈80% of participants had an acute coronary syndrome at the time of inclusion although acute myocardial infarction was present only in a quarter of patients. The analysis of this patient subset did not reveal a greater risk of adverse events with 6-month DAPT. This supports the notion that newgeneration, biodegradable polymer-based DES have addressed the unmet needs of early-generation DES in this setting. [14] [15] [16] However, it should be noted that both the European Society of Cardiology and American College of Cardiology Foundation/ American Heart Association/Society for Cardiac Angiography and Interventions guidelines recommend DAPT for at least 12 months in the absence of contraindications in patients with acute coronary syndrome. 5, 7 Moreover, continuation of thienopyridines on a background of aspirin beyond 1 year in the DAPT trial prevented major adverse cardiovascular and cerebrovascular events to a greater extent in patients with acute myocardial infarction (4.4% versus 5.3%; P=0.08) than among patients without an index presentation of acute myocardial infarction (3.9% versus 6.8%; P<0.001; P for interaction=0.03). 17 In this context, the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI-54) trial showed that longterm ticagrelor treatment in addition to aspirin reduced the risk of major adverse cardiovascular and cerebrovascular events, as well as myocardial infarction and stroke while increasing the risk of major bleeding among 21 162 patients with a history (>1 year) of myocardial infarction. 18 An earlier initiation of ticagrelor monotherapy after new-generation DES is currently tested in the Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-Day Intensive Dual Antiplatelet Therapy in All-Comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-Eluting Stent Use (GLOBAL-LEADERS) trial, which will compare a short course of ticagrelor plus aspirin followed by 23-month ticagrelor monotherapy versus 12-month standard DAPT among 16 000 patients. 19 Thus, the focus is shifting toward antiplatelet strategies that afford long-term prevention against atherothrombotic adverse events while minimizing the risk of bleeding.
Some limitations of the present study are noteworthy. The 1-year rate of target-lesion failure was lower than expected (6.3% versus 8.3%), resulting in a relatively wide margin of noninferiority. Moreover, approximately half of primary end point events occurred during the periprocedural period and therefore well before the timepoint when the 2 randomized treatment regimens actually differed in terms of DAPT duration. In view of the high proportion of patients included with acute coronary syndrome, the use of clopidogrel instead of more potent and effective P2Y 12 receptor inhibitors represents another important limitation. 20 Finally, the extrapolation of trial findings to other biodegradable polymer-based DES is not feasible because of the wide-ranging differences in degradation products and kinetics, which may importantly affect DAPT duration. Furthermore, there remains limited evidence supporting the Firebird DES when compared with other thin-strut, biodegradable polymer DES that have been tested against US Food and Drug Administration-approved, new-generation DES. [21] [22] [23] In summary, the I-LOVE-IT 2 trial reports noninferiority of 6-month versus 12-month DAPT with respect to the primary end point target-lesion failure in a cohort of patients undergoing PCI with a new-generation, biodegradable polymer-based DES. How can we reconcile the differences between trials investigating DAPT ≤12 months versus beyond 1 year? Unfortunately, a definitive answer cannot be provided at the present time. However, it is plausible that trials investigating DAPT duration beyond 1 year are more likely to capture atherothrombotic manifestations, particularly outside the stented coronary segments. In contrast, trials investigating different DAPT durations within 1 year are more sensitive to stent-related adverse events linked to the arterial healing processes. The advent of DAPT >2 decades ago importantly contributed to improve safety and efficacy of PCI and, as a result, its widespread diffusion in clinical practice. In the meantime, various iterations in coronary stent technology have largely resolved stent-related adverse events with rates of definite stent thrombosis amounting to <0.50% per 100 person-years with new-generation DES. 24 Accordingly, the optimal DAPT duration will largely be determined by the prevention of new atherothrombotic events rather than the nuisance of stentrelated thrombotic complications, and novel, more personalized concepts toward the optimal DAPT duration are under clinical investigation.
Disclosures
Dr Windecker has received research grants to the institution from Abbott, Biotronik, Boston Scientific, Biosensors, Medtronic, Edwards, and St Jude. Dr Piccolo reports no conflicts.
